Manufaturing and production news from the pharmaceutical industry
BioNTech has announced that it has reached the next milestone in the establishment of its mRNA vaccine manufacturing capacities in Africa, with the introduction of the new site in Kigali, Rwanda.
Novo Nordisk has announced plans to invest over 42bn Danish kroner to expand its existing manufacturing facilities in Kalundbord, Denmark, for production of the company’s current and future product portfolio within serious chronic diseases.
GSK has announced that in 2024 it intends to start phase 3 trials of a low carbon version of its metered-dose inhaler ventolin (salbutamol) using a next-generation propellant.
Prange Group and Adragos Pharma have announced the signing of definitive agreements with Fresenius Kabi for their acquisition of its leading sterile pharmaceutical production site in Halden, Norway.
Merck has announced that it has invested €35m in biosafety testing at its sites in Glasgow and Stirling, both Scotland.
Medtronic has received the CE mark for its extravascular defibrillator. The Aurora EV-ICD MRI SureScan and epsila EV MRI SureScan defibrillation lead treat abnormally fast heart rhythms, which can lead to sudden cardiac arrest.
US biotech firm Moderna has chosen Harwell Science Campus in Oxfordshire for its new UK R&D facility. The campus is already home to more than 70 organisations and sits within the UK’s ‘golden triangle’, an area rich in life sciences facilities, between Oxford, Cambridge and London.
REGENXBIO, a clinical-stage biotech company, has announced positive phase 2 data for its drug rxg-314, which was developed by the company’s NAVXpress bioreactor platform process.
J&J has begun scaling back its COVID-19 vaccine producation due to the falling demand for the jabs
Eli Lilly has announced plans to invest $450m in manufacturing facilities at Research Triangle Park in North Carolina, US
Daiichi Sankyo shares plans to build its first mRNA COVID-19 vaccine factory in Japan
Sarepta Therapeutics is a company focused on gene therapy, RNA and gene editing, engineering precision genetic medication for rare diseases. It has announced the signing of a commercial supply agreement with Catalent that will allow the company to manufacture delandistrogene moxeparvovec (SRP-9001), Sarepta’s most advanced gene therapy candidate for the treatment of Duchenne muscular dystrophy (DMD).